Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering…
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Apple borrowed $8.5 billion Monday in a four-part bond deal. Why? Because right now, money is cheap.
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Amgen, Cerner, eBay, Gap, Nike, Nucor, Procter & Gamble, TJX and ViacomCBS.
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
